Company news
Rein Therapeutics, Inc. (NASDAQ:RNTX) news
Rein Therapeutics, Inc. news releases on 6ix. Latest, Feb 21, 2023: Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial…
Press releases — page 2
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
February 20, 2023
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
November 29, 2022
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
November 9, 2022
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
October 31, 2022
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
October 25, 2022
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
September 29, 2022
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
September 21, 2022
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 14, 2022
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
July 31, 2022
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
July 7, 2022
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
June 28, 2022
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
May 18, 2022
Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
May 12, 2022
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Ann...
May 9, 2022
Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 4, 2022
Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations
April 20, 2022
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 27, 2022
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference
March 21, 2022
Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones
January 4, 2022
Aileron Therapeutics to Present at Upcoming Investor Conferences
January 3, 2022
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
December 19, 2021
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
November 11, 2021
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
October 6, 2021
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
September 29, 2021
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
September 15, 2021
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
September 6, 2021
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
August 26, 2021
Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 10, 2021
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
July 7, 2021
Aileron Therapeutics to be Added to the Russell Microcap® Index
June 23, 2021
Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
May 18, 2021
Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
March 23, 2021
Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference
March 3, 2021
Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
March 1, 2021
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
January 10, 2021
Aileron Therapeutics Announces $35.9 Million Registered Direct Offering
January 5, 2021
Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
November 11, 2020
Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
October 23, 2020
Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium
October 11, 2020
Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
September 20, 2020
Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 4, 2020
Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August
August 2, 2020
Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924
August 2, 2020
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
June 9, 2020
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock
June 3, 2020
Aileron Therapeutics Announces Proposed Public Offering of Common Stock
June 2, 2020
Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer
May 31, 2020